Fig. 1

Molecular and clinical feature differences in GBM by sex. A–D Patient counts (A), patient age (B), IDH mutation ratio (C), and MGMT status (D) were obtained from The Cancer Genome Atlas (TCGA) (left) and The Glioma Longitudinal Analysis (GLASS) (right). M represents MGMT promoter methylation, and U represents MGMT promoter unmethylation. E Overall survival was analyzed using Kaplan–Meier in a dataset of male and female patients from TCGA and GLASS. F Post-recurrent survival was analyzed using Kaplan–Meier in a dataset of male and female patients from GLASS. G Hypermutation (more than 10 mutations per Mb) ratio was obtained in all GLASS recurrent GBM patients and deteriorated patients of GLASS. *p < 0.05